Listed

Arrowhead Pharmaceuticals, Inc.

ARWRNasdaqCIK 879407HealthcareFiscal year ends Sep 30

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$75.3m, Q3 FY2026
Operating income−$170.1m, Q3 FY2026
Net income−$194.3m, Q3 FY2026
Arrowhead Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ4 FY20232023-09-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30Q4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Revenue$m16.1Revenue, Q4 FY2023, three months to 2023-09-30$16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure3.6Revenue, Q1 FY2024, three months to 2023-12-31$3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure2.5Revenue, Q1 FY2025, three months to 2024-12-31$2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure543Revenue, Q2 FY2025, three months to 2025-03-31$542.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure27.8Revenue, Q3 FY2025, three months to 2025-06-30$27.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure256Revenue, Q4 FY2025, three months to 2025-09-30$256.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure264Revenue, Q1 FY2026, three months to 2025-12-31$264.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure73.7Revenue, Q2 FY2026, three months to 2026-03-31$73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure75.3Revenue, Q3 FY2026, three months to 2026-06-30$75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Research and development$mnot reportednot reportednot reportednot reportednot reported137Research and development, Q1 FY2025, three months to 2024-12-31$137.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure133Research and development, Q2 FY2025, three months to 2025-03-31$133.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure162Research and development, Q3 FY2025, three months to 2025-06-30$162.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure175Research and development, Q4 FY2025, three months to 2025-09-30$174.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure177Research and development, Q1 FY2026, three months to 2025-12-31$177.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure173Research and development, Q2 FY2026, three months to 2026-03-31$173.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure198Research and development, Q3 FY2026, three months to 2026-06-30$198.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Selling, general and administrative$mnot reportednot reportednot reportednot reportednot reportednot reported28.4Selling, general and administrative, Q2 FY2025, three months to 2025-03-31$28.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure30.9Selling, general and administrative, Q3 FY2025, three months to 2025-06-30$30.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figurenot reportednot reported41.7Selling, general and administrative, Q2 FY2026, three months to 2026-03-31$41.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure47.1Selling, general and administrative, Q3 FY2026, three months to 2026-06-30$47.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Operating income$m(108)Operating income, Q4 FY2023, three months to 2023-09-30−$108.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(137)Operating income, Q1 FY2024, three months to 2023-12-31−$136.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure(126)Operating income, Q2 FY2024, three months to 2024-03-31−$126.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure(176)Operating income, Q3 FY2024, three months to 2024-06-30−$176.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure(162)Operating income, Q4 FY2024, three months to 2024-09-30−$162.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(161)Operating income, Q1 FY2025, three months to 2024-12-31−$161.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure381Operating income, Q2 FY2025, three months to 2025-03-31$381.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(166)Operating income, Q3 FY2025, three months to 2025-06-30−$165.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure44.1Operating income, Q4 FY2025, three months to 2025-09-30$44.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure40.8Operating income, Q1 FY2026, three months to 2025-12-31$40.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(141)Operating income, Q2 FY2026, three months to 2026-03-31−$141.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(170)Operating income, Q3 FY2026, three months to 2026-06-30−$170.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Interest expense$m5.3Interest expense, Q4 FY2023, three months to 2023-09-30$5.3m. XBRL concept us-gaap:InterestExpense. 10-K filed 2023-11-29, accession 0001628280-23-040219. Derived: 12-month figure less the 9-month figure.Report this figure5.4Interest expense, Q1 FY2024, three months to 2023-12-31$5.4m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure7.2Interest expense, Q2 FY2024, three months to 2024-03-31$7.2m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure5.1Interest expense, Q3 FY2024, three months to 2024-06-30$5.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure14.6Interest expense, Q4 FY2024, three months to 2024-09-30$14.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure21.6Interest expense, Q1 FY2025, three months to 2024-12-31$21.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure21.6Interest expense, Q2 FY2025, three months to 2025-03-31$21.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure24.4Interest expense, Q3 FY2025, three months to 2025-06-30$24.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure21.7Interest expense, Q4 FY2025, three months to 2025-09-30$21.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure22.5Interest expense, Q1 FY2026, three months to 2025-12-31$22.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure23.8Interest expense, Q2 FY2026, three months to 2026-03-31$23.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure24.6Interest expense, Q3 FY2026, three months to 2026-06-30$24.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Income tax$m2.0Income tax, Q4 FY2023, three months to 2023-09-30$2.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(3.3)Income tax, Q1 FY2024, three months to 2023-12-31−$3.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure0.5Income tax, Q4 FY2024, three months to 2024-09-30$546.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2025, three months to 2024-12-31$103.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure1.8Income tax, Q2 FY2025, three months to 2025-03-31$1.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(0.4)Income tax, Q3 FY2025, three months to 2025-06-30−$437.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure20.0Income tax, Q4 FY2025, three months to 2025-09-30$20.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2025-12-31$29.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-03-31$7.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure0.0Income tax, Q3 FY2026, three months to 2026-06-30$11.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Net income$m(110)Net income, Q4 FY2023, three months to 2023-09-30−$109.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(133)Net income, Q1 FY2024, three months to 2023-12-31−$132.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure(125)Net income, Q2 FY2024, three months to 2024-03-31−$125.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure(171)Net income, Q3 FY2024, three months to 2024-06-30−$170.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure(171)Net income, Q4 FY2024, three months to 2024-09-30−$170.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(173)Net income, Q1 FY2025, three months to 2024-12-31−$173.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure370Net income, Q2 FY2025, three months to 2025-03-31$370.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(175)Net income, Q3 FY2025, three months to 2025-06-30−$175.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure(23.8)Net income, Q4 FY2025, three months to 2025-09-30−$23.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure30.8Net income, Q1 FY2026, three months to 2025-12-31$30.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(133)Net income, Q2 FY2026, three months to 2026-03-31−$132.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(194)Net income, Q3 FY2026, three months to 2026-06-30−$194.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Diluted EPS$ per sharenot reported(1.24)Diluted EPS, Q1 FY2024, three months to 2023-12-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure(1.02)Diluted EPS, Q2 FY2024, three months to 2024-03-31−$1.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure(1.38)Diluted EPS, Q3 FY2024, three months to 2024-06-30−$1.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figurenot reported(1.39)Diluted EPS, Q1 FY2025, three months to 2024-12-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure2.75Diluted EPS, Q2 FY2025, three months to 2025-03-31$2.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(1.26)Diluted EPS, Q3 FY2025, three months to 2025-06-30−$1.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figurenot reported0.22Diluted EPS, Q1 FY2026, three months to 2025-12-31$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(0.93)Diluted EPS, Q2 FY2026, three months to 2026-03-31−$0.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(1.36)Diluted EPS, Q3 FY2026, three months to 2026-06-30−$1.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Basic EPS$ per sharenot reported(1.24)Basic EPS, Q1 FY2024, three months to 2023-12-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure(1.02)Basic EPS, Q2 FY2024, three months to 2024-03-31−$1.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure(1.38)Basic EPS, Q3 FY2024, three months to 2024-06-30−$1.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figurenot reported(1.39)Basic EPS, Q1 FY2025, three months to 2024-12-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure2.78Basic EPS, Q2 FY2025, three months to 2025-03-31$2.78 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(1.26)Basic EPS, Q3 FY2025, three months to 2025-06-30−$1.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figurenot reported0.22Basic EPS, Q1 FY2026, three months to 2025-12-31$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(0.93)Basic EPS, Q2 FY2026, three months to 2026-03-31−$0.93 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(1.36)Basic EPS, Q3 FY2026, three months to 2026-06-30−$1.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure

Balance sheet

Cash and equivalents$69.4m, Q3 FY2024
Shareholders' equity$465.5m, Q3 FY2026
Arrowhead Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitFY20232023-09-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Cash and equivalents$mnot reported58.2Cash and equivalents, Q1 FY2024, at 2023-12-31$58.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure128Cash and equivalents, Q2 FY2024, at 2024-03-31$127.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure69.4Cash and equivalents, Q3 FY2024, at 2024-06-30$69.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001628280-24-036104.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current assets$m416Current assets, FY2023, at 2023-09-30$416.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure238Current assets, Q1 FY2024, at 2023-12-31$237.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure542Current assets, Q2 FY2024, at 2024-03-31$541.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure450Current assets, Q3 FY2024, at 2024-06-30$450.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-036104.Report this figure695Current assets, FY2024, at 2024-09-30$695.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure571Current assets, Q1 FY2025, at 2024-12-31$570.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure1,135Current assets, Q2 FY2025, at 2025-03-31$1.14bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure947Current assets, Q3 FY2025, at 2025-06-30$946.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure951Current assets, FY2025, at 2025-09-30$950.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure1,174Current assets, Q1 FY2026, at 2025-12-31$1.17bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure1,840Current assets, Q2 FY2026, at 2026-03-31$1.84bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure1,671Current assets, Q3 FY2026, at 2026-06-30$1.67bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Total assets$m766Total assets, FY2023, at 2023-09-30$765.6m. XBRL concept us-gaap:Assets. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure626Total assets, Q1 FY2024, at 2023-12-31$626.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure955Total assets, Q2 FY2024, at 2024-03-31$955.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure884Total assets, Q3 FY2024, at 2024-06-30$883.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001628280-24-036104.Report this figure1,140Total assets, FY2024, at 2024-09-30$1.14bn. XBRL concept us-gaap:Assets. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure1,014Total assets, Q1 FY2025, at 2024-12-31$1.01bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure1,573Total assets, Q2 FY2025, at 2025-03-31$1.57bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure1,381Total assets, Q3 FY2025, at 2025-06-30$1.38bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure1,385Total assets, FY2025, at 2025-09-30$1.39bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure1,604Total assets, Q1 FY2026, at 2025-12-31$1.60bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure2,268Total assets, Q2 FY2026, at 2026-03-31$2.27bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure2,112Total assets, Q3 FY2026, at 2026-06-30$2.11bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Current liabilities$m105Current liabilities, FY2023, at 2023-09-30$105.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure63.7Current liabilities, Q1 FY2024, at 2023-12-31$63.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure65.2Current liabilities, Q2 FY2024, at 2024-03-31$65.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure96.7Current liabilities, Q3 FY2024, at 2024-06-30$96.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-036104.Report this figure103Current liabilities, FY2024, at 2024-09-30$103.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure93.8Current liabilities, Q1 FY2025, at 2024-12-31$93.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure221Current liabilities, Q2 FY2025, at 2025-03-31$220.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure195Current liabilities, Q3 FY2025, at 2025-06-30$194.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure195Current liabilities, FY2025, at 2025-09-30$195.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure347Current liabilities, Q1 FY2026, at 2025-12-31$347.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure295Current liabilities, Q2 FY2026, at 2026-03-31$295.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure283Current liabilities, Q3 FY2026, at 2026-06-30$283.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Shareholders' equity$m271Shareholders' equity, FY2023, at 2023-09-30$271.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure160Shareholders' equity, Q1 FY2024, at 2023-12-31$160.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure484Shareholders' equity, Q2 FY2024, at 2024-03-31$483.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure331Shareholders' equity, Q3 FY2024, at 2024-06-30$330.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-08, accession 0001628280-24-036104.Report this figure185Shareholders' equity, FY2024, at 2024-09-30$185.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure52.6Shareholders' equity, Q1 FY2025, at 2024-12-31$52.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure683Shareholders' equity, Q2 FY2025, at 2025-03-31$683.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure522Shareholders' equity, Q3 FY2025, at 2025-06-30$522.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure466Shareholders' equity, FY2025, at 2025-09-30$466.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure568Shareholders' equity, Q1 FY2026, at 2025-12-31$568.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure614Shareholders' equity, Q2 FY2026, at 2026-03-31$614.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure466Shareholders' equity, Q3 FY2026, at 2026-06-30$465.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure

Cash flow

Operating cash flow−$177.5m, Q3 FY2026
Capital expenditure$3.9m, Q3 FY2026
Arrowhead Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ4 FY20232023-09-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30Q4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Operating cash flow$m(25.9)Operating cash flow, Q4 FY2023, three months to 2023-09-30−$25.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(118)Operating cash flow, Q1 FY2024, three months to 2023-12-31−$117.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure(92.4)Operating cash flow, Q2 FY2024, three months to 2024-03-31−$92.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001628280-25-024666. Derived: 6-month figure less the 3-month figure.Report this figure(115)Operating cash flow, Q3 FY2024, three months to 2024-06-30−$115.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001628280-25-038858. Derived: 9-month figure less the 6-month figure.Report this figure(137)Operating cash flow, Q4 FY2024, three months to 2024-09-30−$137.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(146)Operating cash flow, Q1 FY2025, three months to 2024-12-31−$146.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure460Operating cash flow, Q2 FY2025, three months to 2025-03-31$460.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure(155)Operating cash flow, Q3 FY2025, three months to 2025-06-30−$154.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure20.5Operating cash flow, Q4 FY2025, three months to 2025-09-30$20.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure13.5Operating cash flow, Q1 FY2026, three months to 2025-12-31$13.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure84.4Operating cash flow, Q2 FY2026, three months to 2026-03-31$84.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure(177)Operating cash flow, Q3 FY2026, three months to 2026-06-30−$177.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$m63.9Capital expenditure, Q4 FY2023, three months to 2023-09-30$63.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure68.7Capital expenditure, Q1 FY2024, three months to 2023-12-31$68.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure34.1Capital expenditure, Q2 FY2024, three months to 2024-03-31$34.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001628280-25-024666. Derived: 6-month figure less the 3-month figure.Report this figure14.4Capital expenditure, Q3 FY2024, three months to 2024-06-30$14.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001628280-25-038858. Derived: 9-month figure less the 6-month figure.Report this figure24.3Capital expenditure, Q4 FY2024, three months to 2024-09-30$24.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure7.5Capital expenditure, Q1 FY2025, three months to 2024-12-31$7.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure5.3Capital expenditure, Q2 FY2025, three months to 2025-03-31$5.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure2.4Capital expenditure, Q3 FY2025, three months to 2025-06-30$2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure7.5Capital expenditure, Q4 FY2025, three months to 2025-09-30$7.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure2.1Capital expenditure, Q1 FY2026, three months to 2025-12-31$2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure2.6Capital expenditure, Q2 FY2026, three months to 2026-03-31$2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure3.9Capital expenditure, Q3 FY2026, three months to 2026-06-30$3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure

Shares

Diluted shares (weighted)143.38m, Q3 FY2026
Arrowhead Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ1 FY20232022-12-31Q2 FY20232023-03-31Q3 FY20232023-06-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Diluted shares (weighted)m shares106Diluted shares (weighted), Q1 FY2023, three months to 2022-12-31106,039,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-02-06, accession 0001628280-24-003492.Report this figure108Diluted shares (weighted), Q2 FY2023, three months to 2023-03-31108,143,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001628280-24-022215.Report this figure107Diluted shares (weighted), Q3 FY2023, three months to 2023-06-30107,004,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001628280-24-036104.Report this figure107Diluted shares (weighted), Q1 FY2024, three months to 2023-12-31107,415,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-02-10, accession 0001628280-25-004634.Report this figure123Diluted shares (weighted), Q2 FY2024, three months to 2024-03-31123,285,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001628280-25-024666.Report this figure124Diluted shares (weighted), Q3 FY2024, three months to 2024-06-30124,199,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001628280-25-038858.Report this figure125Diluted shares (weighted), Q1 FY2025, three months to 2024-12-31124,848,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure134Diluted shares (weighted), Q2 FY2025, three months to 2025-03-31134,484,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure139Diluted shares (weighted), Q3 FY2025, three months to 2025-06-30139,039,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure141Diluted shares (weighted), Q1 FY2026, three months to 2025-12-31140,706,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure142Diluted shares (weighted), Q2 FY2026, three months to 2026-03-31142,417,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure143Diluted shares (weighted), Q3 FY2026, three months to 2026-06-30143,378,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure

Shares outstanding: 141.25mShares outstanding, period not labelled, at 2026-07-30141,254,467 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure at Jul 30, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. Listed shows no prices and gives no investment advice.